Comparative Pharmacology
Head-to-head clinical analysis: ARAMINE versus VASOSTRICT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ARAMINE versus VASOSTRICT.
ARAMINE vs VASOSTRICT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Direct-acting sympathomimetic amine that stimulates alpha-adrenergic receptors, causing vasoconstriction and increased blood pressure.
Vasopressin is a synthetic analogue of the antidiuretic hormone (ADH) that acts on V1 receptors (vascular smooth muscle) to cause vasoconstriction, and on V2 receptors (renal collecting ducts) to increase water reabsorption. At high doses used in vasodilatory shock, it primarily increases systemic vascular resistance via V1 receptor activation.
Intravenous infusion: 1-10 mg initially, then 0.5-5 mg/hr titrated to blood pressure. Intramuscular or subcutaneous: 2-10 mg every 2 hours as needed.
0.01-0.03 units/min IV continuous infusion, titrate to effect. Maximum 0.1 units/min.
None Documented
None Documented
Terminal elimination half-life is 2-4 hours. Clinical context: Requires continuous infusion for sustained blood pressure support.
Terminal elimination half-life is approximately 10–20 minutes, with clinical effect terminated rapidly by enzymatic degradation (catechol-O-methyltransferase and monoamine oxidase) in the liver and other tissues.
Primarily renal: 85% unchanged drug in urine within 24 hours. Biliary/fecal: <5%.
Primarily renal (90–95% as inactive metabolites); minor biliary/fecal excretion (<5%).
Category C
Category C
Vasopressor
Vasopressor